Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jennifer M Stephens, Xin Gao, Dipen A Patel, Bram G Verheggen, Ahmed Shelbaya & Seema Haider. (2013) Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. ClinicoEconomics and Outcomes Research 5, pages 447-457.
Read now
Read now
Sally Ager & Kate Gould. (2012) Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infection and Drug Resistance 5, pages 87-102.
Read now
Read now
Santiago Grau & Carlos Rubio-Terrés. (2008) Pharmacoeconomics of linezolid. Expert Opinion on Pharmacotherapy 9:6, pages 987-1000.
Read now
Read now
Articles from other publishers (17)
J.F. Huon, D. Boutoille, J. Caillon, J. Orain, N. Crochette, G. Potel, P. Abgueguen, F. Moal & D. Navas. (2020) Linezolid versus vancomycin cost in the treatment of staphylococcal pneumonia. Médecine et Maladies Infectieuses 50:3, pages 252-256.
Crossref
Crossref
Sharmila Jasmine, Thangavelu A.K. Janarthanan, Rajapandiyan Krishnamoorthy & Ali A. Alshatwi. (2020) Antimicrobial and antibiofilm potential of injectable platelet rich fibrin—a second-generation platelet concentrate—against biofilm producing oral staphylococcus isolates. Saudi Journal of Biological Sciences 27:1, pages 41-46.
Crossref
Crossref
E. von Dach, C.M. Morel, A. Murthy, L. Pagani, M. Macedo-Vinas, F. Olearo & S. Harbarth. (2017) Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective. Clinical Microbiology and Infection 23:9, pages 659-666.
Crossref
Crossref
E D Mitchell, C Czoski Murray, D Meads, J Minton, J Wright & M Twiddy. (2017)
Clinical and cost-effectiveness, safety and acceptability of
c
ommunity
i
ntra
v
enous
a
ntibiotic
s
ervice models: CIVAS systematic review
. BMJ Open 7:4, pages e013560.
Crossref
Crossref
Jane Minton, Carolyn Czoski Murray, David Meads, Stephane Hess, Armando Vargas-Palacios, Elizabeth Mitchell, Judy Wright, Claire Hulme, David K Raynor, Angela Gregson, Philip Stanley, Kate McLintock, Rachel Vincent & Maureen Twiddy. (2017) The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy. Health Services and Delivery Research 5:6, pages 1-272.
Crossref
Crossref
Jirong Yue, Bi Rong Dong, Ming Yang, Xiaomei Chen, Taixiang Wu & Guan J Liu. (2016) Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database of Systematic Reviews.
Crossref
Crossref
G.G. Aubin, S. Corvec, J. Caillon, D. Lepelletier & D. Navas. (2015) Place du linézolide dans la prise en charge de pneumonies nosocomiales à Staphylococcus aureus résistants à la méticilline (SARM). Le Pharmacien Hospitalier et Clinicien 50:1, pages 114-124.
Crossref
Crossref
Talitha I. Verhoef & Stephen Morris. (2015) Cost-effectiveness and Pricing of Antibacterial Drugs. Chemical Biology & Drug Design 85:1, pages 4-13.
Crossref
Crossref
Jirong Yue, Bi Rong Dong, Ming Yang, Xiaomei Chen, Taixiang Wu & Guan J Liu. (2014) Linezolid versus vancomycin for skin and soft tissue infections. Evidence-Based Child Health: A Cochrane Review Journal 9:1, pages 103-166.
Crossref
Crossref
Jirong Yue, Bi Rong Dong, Ming Yang, Xiaomei Chen, Taixiang Wu & Guan J Liu. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Jinjian Fu, Xiaohua Ye, Cha Chen & Sidong Chen. (2013) The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections. PLoS ONE 8:3, pages e58240.
Crossref
Crossref
Ewelina Gaszyńska, Marta Tyndorf, Bogusława Manowska & Piotr Arkuszewski. (2011) Methicillin Resistant Staphylococcus Aureus Infections of Soft Issues of the Oral Cavity, Face and Neck in Patients Hospitalized at the Cranio-maxillofacial Surgery Department. Polish Journal of Surgery 83:4.
Crossref
Crossref
Liang Beibei, Cai Yun, Chen Mengli, Bai Nan, Yu Xuhong & Wang Rui. (2010) Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. International Journal of Antimicrobial Agents 35:1, pages 3-12.
Crossref
Crossref
Burke A. Cunha. 2009. Infectious Diseases in Critical Care Medicine. Infectious Diseases in Critical Care Medicine
497
511
.
Nesrene S. Omar, Mamdouh R. El-Nahas & Jim Gray. (2008) Novel antibiotics for the management of diabetic foot infections. International Journal of Antimicrobial Agents 31:5, pages 411-419.
Crossref
Crossref
. (2013) Linezolid best value in MRSA SSI. PharmacoEconomics & Outcomes News 524:1, pages 1-1.
Crossref
Crossref
Andrew F Shorr. (2007) Epidemiology and Economic Impact??of Meticillin-Resistant Staphylococcus aureus. PharmacoEconomics 25:9, pages 751-768.
Crossref
Crossref